High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: Trowing the urso out with the bathwater?

Hepatology

Volumn 50, Issue 3, 2009, Pages 671-673

  Chapman, Roger W ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; URSODEOXYCHOLIC ACID;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BILE DUCT CANCER; CANCER RISK; CELL PROTECTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CANCER; DETOXIFICATION; DRUG EFFICACY; DRUG MEGADOSE; EDITORIAL; HUMAN; IMMUNOMODULATION; LIVER PROTECTION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK REDUCTION; NOTE; SCLEROSING CHOLANGITIS;

CHOLANGITIS, SCLEROSING; HUMANS; URSODEOXYCHOLIC ACID;

EID: 70349243248     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23174     Document Type: Editorial

References (23)

1. Maggs JR, Chapman RW. An update on primary sclerosing cholangitis. Curr Opin Gastroenterol 2008;24:377-383.
2. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver diseases. HEPATOLOGY 2002;36:525-531.
3. Martinez JD, Stratagoules ED, La Rue JM, Powell AA, Gause PR, Craven MT, et al. Different bile acids exhibit distinct biological effects. Nutr Cancer 1998;31:111-118.
4. Chazouilleres O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990;11:120-123. (Pubitemid 20250837)
5. O'Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. HEPATOLOGY 1991;14:838-847.
6. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. HEPATOLOGY 1992;16:707-714.
7. Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994;20:57-64. (Pubitemid 24043086)
8. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691-695.
9. Lindor KD, Kowdley KV, Luketic VAC, Harrison ME, McCashland T, Befeler AS, et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. HEPATOLOGY 2009; doi:10.1002/hep.23082.
10. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-907. (Pubitemid 32959399)
11. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-1472.
12. Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman W. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008;48:792-800.
13. Harnois DM, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001:96:1558-1562. (Pubitemid 32455090)
14. Fickert P, Zollner G, Fuchsbichler A, Stumpter C, Weiglen AH, Lammert F, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002;123:1238-1251.
15. Beneditti A, Alvaro D, Bassotti C, Gigliozzi A, Ferretti G, La Rosa T, et al. Cytotoxicity of bile salts against biliary epithelium:a study in isolated bie ductile fragments and isolated perfused rat liver. HEPATOLOGY 1997;26:9-21. (Pubitemid 27280301)
16. Glaser SS, Alpini G, Hightower NC. Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis. HEPATOLOGY 2009;49:1790-1792.
17. Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr-/- mice. HEPATOLOGY 2009;49:1972-1982.
18. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134: 89-95.
19. Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005;22:783-788.
20. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-893. (Pubitemid 36389790)
21. Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2007;19:487-491. (Pubitemid 46725755)
22. Brandsaeter B, Isoniemi H, Broomé U, Olausson M, Bäckman L, Hansen B, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004;40:815-822. (Pubitemid 38507363)
23. Okolicsanyi L, Groppo M, Floreani A, Morselli-Labate AM, Rusticali AG, Battocchia A, et al. Treatment of primary sclerosing cholangitis with lowdose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Dig Liver Dis 2003;35:325-331. (Pubitemid 41110859)